The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Trilok Potluri & PACs
SMSPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
On 10 September 2025, SMS Pharmaceuticals allotted 50,00,000 equity shares (face value Re.1) to promoter Trilok Potluri (25 lakh) and PAC Vamsi Krishna Potluri (25 lakh) on conversion of an equal number of warrants through preferential allotment. After the conversion, Trilok Potluri's direct equity stake rose from 2.47% to 5.29%, while Vamsi Krishna Potluri's rose from 15.03% to 17.85%. The total promoter and PAC group's combined holding remains unchanged at 71.90% of total share capital (68.07% on a fully diluted basis), as the warrants were already counted in pre-acquisition holding. Total equity share capital increased from Rs.8.87 crore to Rs.9.37 crore. No new funds appear to have been raised from the market — these are pre-existing warrants being converted after receipt of the balance amount.
For retail shareholders, this means mild further dilution of their stake (their share of equity dropped proportionally as 50 lakh new shares were issued) but no change in promoter control. The promoter group stays comfortably above 50%, indicating strong promoter commitment, though at 71.90% they are nearing the 75% upper cap on non-public shareholding under SEBI takeover rules, which limits room for further promoter-side accumulation without triggering an open offer.